c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: A retrospective study

Breast Cancer Research

Volumn 7, Issue 3, 2005, Pages

  Fritz, Peter ^a   Cabrera, Cristina M ^b   Dippon, Jürgen ^c   Gerteis, Andreas ^a   Simon, Wolfgang ^a   Aulitzky, Walter E ^a   van der Kuip, Heiko ^b  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; TOPOISOMERASE IIALPHA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; STAINING; VERY ELDERLY; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 27644452196     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1012     Document Type: Article

References (30)

1. Yu DH, Hung MC: Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene. 1991, 6: 1991-1996.
2. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ: HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002, 8: 1107-1116.
3. Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD: Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002, 8: 1061-1067.
4. Park K, Kim J, Lim S, Han S: Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003, 39: 631-634. 10.1016/S0959-8049(02)00745-1.
5. Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ, et al: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol. 2004, 24: 201-209.
6. Di Leo A, Isola J: Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?. Clin Breast Cancer. 2003, 4: 179-186.
7. Stern DF, Heffernan PA, Weinberg RA: p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol. 1986, 6: 1729-1740.
8. Eccles SA: The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia. 2001, 6: 393-406. 10.1023/A:1014730829872.
9. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003, 8: 307-325. 10.1634/theoncologist.8-4-307.
10. Wang JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002, 3: 430-440. 10.1038/nrm831.
11. Jarvinen TA, Liu ET: HER-2/neu and topoisomerase IIalpha - simultaneous drug targets in cancer. Comb Chem High Throughput Screen. 2003, 6: 455-470.
12. Keith WN, Douglas F, Wishart GC, McCallum HM, George WD, Kaye SB, Brown R: Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer. 1993, 29A: 1469-1475. 10.1016/0959-8049(93)90022-8.
13. Murphy DS, McHardy P, Coutts J, Mallon EA, George WD, Kaye SB, Brown R, Keith WN: Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer. 1995, 64: 18-26.
14. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J: Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer. 1999, 26: 142-150.
15. Jarvinen TA, Kononen J, Pelto-Huikko M, Isola J: Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol. 1996, 148: 2073-2082.
16. Durbecq V, Desmedt C, Paesmans M, Cardoso F, Di Leo A, Mano M, Rouas G, Leroy J-Y, Sotiriou C, Piccart M, et al: Correlation between topoisomerase IIalpha gene amplification and protein expression in Her-2 amplified breast cancer. Int J Oncol. 2004, 25: 1473-1479.
17. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003, 100: 10393-10398. 10.1073/pnas.1732912100.
18. Bakshi RP, Galande S, Muniyappa K: Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase. Crit Rev Biochem Mol Biol. 2001, 36: 1-37.
19. The World Health Organization: Histological typing of breast tumors. Neoplasma. 1983, 30: 113-123.
20. Tuczek HV, Fritz P, Oeffinger B, Limbach HJ, Mischlinski A, Klein C, Wegner G: Interpretation of the estrogen receptor content of breast cancer. Geburtshilfe Frauenheilkd. 1990, 50: 314-318.
21. Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, Harris AL: Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J. 1996, 73: 1518-1524.
22. Hortobagyi GN: Treatment of breast cancer. N Engl J Med. 1998, 339: 974-984. 10.1056/NEJM199810013391407.
23. Rudolph P, MacGrogan G, Bonichon F, Frahm SO, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM, Parwaresch R: Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat. 1999, 55: 61-71. 10.1023/A:1006159016703.
24. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J: Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000, 156: 839-847.
25. Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES: Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J. 1996, 319: 307-313.
26. Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegele P, Eber M, Ghnassia JP: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004, 40: 205-211. 10.1016/S0959-8049(03)00675-0.
27. Nakopoulou L, Lazaris AC, Kavantzas N, Alexandrou P, Athanassiadou P, Keramopoulos A, Davaris P: DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology. 2000, 68: 137-143. 10.1159/000055914.
28. Akimitsu N, Adachi N, Hirai H, Hossain MS, Hamamoto H, Kobayashi M, Aratani Y, Koyama H, Sekimizu K: Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIalpha. Genes Cells. 2003, 8: 393-402. 10.1046/j.1365-2443.2003.00643.x.
29. Akimitsu N, Kamura K, Tone S, Sakaguchi A, Kikuchi A, Hamamoto H, Sekimizu K: Induction of apoptosis by depletion of DNA topoisomerase IIalpha in mammalian cells. Biochem Biophys Res Commun. 2003, 307: 301-307. 10.1016/S0006-291X(03)01169-0.
30. McPherson JP, Goldenberg GJ: Induction of apoptosis by deregulated expression of DNA topoisomerase IIalpha. Cancer Res. 1998, 58: 4519-4524.